Disulfiram

views updated

Disulfiram

Definition

Purpose

Description

Recommended dosage

Precautions

Side effects

Interactions

Resources

Definition

Disulfiram is an aldehyde dehydrogenase inhibitor. It prohibits the activity of aldehyde dehydrogenase, an enzyme found in the liver. In the United States, disulfiram is sold under brand name Antabuse.

Purpose

Disulfiram is used as a conditioning treatment for alcohol dependence. When taken with alcohol, disulfiram causes many unwanted and unpleasant effects, and the fear of these is meant to condition the patient to avoid alcohol.

Description

Two Danish physicians who were investigating disulfiram for its potential benefits to destroy parasitic worms took disulfiram and became sick at a cocktail party. After a series of pharmacological and clinical studies, it was determined that disulfiram interacts with alcohol.

Disulfiram by itself is not toxic. If taken with alcohol, however, it alters certain steps in the breakdown of alcohol. When alcohol is ingested, it is converted first to a chemical called acetaldehyde. Acetaldehyde is further broken down into acetate. In order for acetaldehyde to be broken down into acetate, aldehyde dehydrogenase needs to be active. Disulfiram is an aldehyde dehydrogenase inhibitor. Since disulfiram blocks the activity of aldehyde dehydrogenase, acetaldehyde cannot be broken down and the levels of acetaldehyde become five to ten times higher than the normal levels. This causes uncomfortable effects that encourage the person to avoid alcohol.

Disulfiram comes in a 250- and 500-mg tablet.

Recommended dosage

Disulfiram therapy should be started only after the patient has abstained from alcohol for at least 12 hours. The initial dose may be as high as 500 mg taken once daily. If the medication is sedating, the dose can be administered in the evening. Ideally, though, the daily dose should be taken in the morning—the time the resolve not to drink may be strongest. The initial dosing period can last for one to two weeks.

A maintenance dose can range anywhere from 125-500 mg daily with the average dose being 250 mg daily. Disulfiram therapy should continue until full recovery. This may take months to years, depending upon the patient’s response and motivation to stop using alcohol. The duration of disulfiram’s activity is 14 days after discontinuation, and patients need to avoid alcohol for this period of time.

Precautions

Before beginning therapy, patients should be carefully evaluated for their intellectual capacity to understand the goal of therapy, which can be described as behavioral modification with negative reinforcement. Patients with history of psychosis , severe myocardial disease, and coronary occlusion should not take disulfiram. People with diabetes taking disulfiram are at an increased risk for complications. Severe liver failure has been associated with the use of disulfiram in patients with or without a prior history of liver problems. People with advanced or severe liver disease should not take disulfiram. Disulfiram should never be given to patients who are in a state of alcohol intoxication or without the patient’s knowledge. Those patients with history of seizures , hypothyroidism, or nephritis need to use disulfiram with caution and close monitoring.

Besides avoiding alcohol, patients should also avoid any products containing alcohol. This includes many cold syrups, tonics, and mouthwashes. Patients

KEY TERMS

Coronary occlusion —Blockage of the arteries supplying the blood to the heart.

Hypothyroidism —Thyroid gland that is abnormally low-functioning. A lowered metabolic rate results.

Jaundice —A yellowing of the skin caused by excess bilirubin in the blood; a liver disorder.

MAO inhibitors —A group of antidepressant drugs that decrease the activity of monoamine oxidase, a neurotransmitter found in the brain that affects mood.

Myocardial disease —Disease of the muscular layer of the heart wall.

Nephritis —Inflammation of the kidney.

Psychosis —Severe state that is characterized by loss of contact with reality and deterioration in normal social functioning; examples are schizophrenia and paranoia. Psychosis is usually one feature of an overarching disorder, not a disorder in itself. (Plural: psychoses)

should not even use topical preparations that contain alcohol such as perfume and aftershave lotion.

Side effects

The most common side effect of disulfiram includes drowsiness and fatigue. Many patients experience metallic or garlic-like aftertaste, but most patients develop tolerance to this effect.

In addition, disulfiram is also associated with impotence. This is most common in doses of 500 mg daily. Disulfiram can also cause blurred vision, skin discoloration, inflammation of the skin, increased heart rate, and mental changes.

During the first three months of therapy, patients should have their liver function evaluated. Patients need to be monitored for the signs of jaundice, nausea, vomiting, abdominal pain, light stools, and dark urine as these may be the signs of liver damage due to disulfiram. The signs of alcohol ingestion include flushing, headache, nausea, vomiting and abdominal pain.

Interactions

Disulfiram can make cisapride, benzodiazepines , astemizole, cyclosporine, erythromycin, and cholesterol-lowering drugs called statins more toxic. Disulfiram in combination with isoniazid, monoamine oxidase inhibitors (MAOIs) (such as phenelzide and tranylcypromine ), metronidazole, omeprazole and tricyclic antidepressants may cause adverse central nervous system effects.

In addition, disulfiram may raise the concentrations of the medications theophylline and phenytoin in the body. Disulfiram may put patients on warfarin (a blood-thinning drug) at an increased risk of bleeding. Disulfiram should never be used with tranylcypromine and amprenavir oral solution.

Disulfiram may react even with small amounts of alcohol found in over-the-counter cough and cold preparations and any medication that comes in an elixir form.

Resources

BOOKS

Lacy, Charles. Drug Information Handbook. Hudson, OH: Lexi-Comp, 2002.

Taylor, David, Robert Kerwin, and Carol Paton. The Maudsley 2005-2006 Prescribing Guidelines. New York: Taylor and Francis, 2005.

PERIODICALS

Berglund, Mats. “A Better Widget? Three Lessons for Improving Addiction Treatment from a Meta-Analytical Study.” Addiction 100.6 (June 2005): 742–50.

Boothby, Lisa, A., and Paul L. Doering. “Acamprosate for the Treatment of Alcohol Dependence.” Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy 27.6 (June 2005): 695–714.

Buonopane, Alessandra, and Ismene L. Petrakis. “Pharmacotherapy of Alcohol Use Disorders.” Substance Use and Misuse 40.13-14 (2005): 2001–20.

Krampe, Henning, and others. “Follow-Up of 180 Alcoholic Patients for Up to 7 Years After Outpatient Treatment: Impact of Alcohol Deterrents on Outcome.” Alcoholism: Clinical and Experimental Research 30 (1) (Jan. 2006): 86–95.

Kulig, Clark C., and Thomas P. Beresford. “Hepatitis C in Alcohol Dependence: Drinking Versus Disulfiram.” Journal of Addictive Diseases 24.2 (2005): 77–89.

Nava, Felice, Stefania Premi, Ezio Manzato, and Alfio Lucchini. “Comparing Treatments of Alcoholism on Craving and Biochemical Measures of Alcohol Consumptions.” Journal of Psychoactive Drugs 38.3 (Sept. 2006): 211–17.

Petrakis, Ismene L., and others. “Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders.” Biological Psychiatry 57.10 (May 2005): 1128–37.

Sofuoglu, Mehmet, and Thomas R. Kosten. “Novel Approaches to the Treatment of Cocaine Addiction.” CNS Drugs 19.1 (2005): 13–25.

Suh, Jesse J., Helen M. Pettinati, Kyle M. Kampman, and Charles P. O’Brien. “The Status of Disulfiram: A Half of a Century Later.” Journal of Clinical Psychopharmacology 26.3 (June 2006): 290–302.

OTHER

Wyeth-Ayerst Laboratories Staff. “Product Information: Antabuse, Disulfiram Tablets.” Philadelphia: Wyeth-Ayerst Laboratories, 2000.

Ajna Hamidovic, Pharm.D.

Ruth A. Wienclaw, PhD

More From encyclopedia.com